Long-Term Follow-Up Still Shows Tafinlar/Mekinist Benefit in Melanoma

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.

Related Keywords

Australia ,Georgina ,Western Australia ,Sydney ,New South Wales ,Tafinlar Mekinist ,University Of Sydney ,New England Journal ,Drug Administration ,